PODD logo

Insulet Corporation (PODD)

$138.97

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on PODD

Market cap

$9.63B

EPS

4.28

P/E ratio

40.2

Price to sales

4.11

Dividend yield

--

Beta

1.125522

Price on PODD

Previous close

$145.76

Today's open

$144.45

Day's range

$138.79 - $144.78

52 week range

$138.79 - $354.88

Profile about PODD

CEO

Ashley McEvoy

Employees

5400

Headquarters

Acton, MA

Exchange

Nasdaq Global Select

Shares outstanding

69264674

Issue type

Common Stock

PODD industries and sectors

Healthcare

Medical Equipment & Supplies

News on PODD

Insulet Corporation (PODD) Discusses Recent Product Recalls and Physician Community Response at ADA Meeting Transcript

Insulet Corporation (PODD) Discusses Recent Product Recalls and Physician Community Response at ADA Meeting Transcript

news source

Seeking Alpha • Jun 12, 2026

news preview

Why Insulet (PODD) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

news source

Zacks Investment Research • Jun 11, 2026

news preview

Insulet Corporation Valuation Pressure Has Dropped Enough (Upgrade)

Insulet Corporation has rebounded with strong revenue and profit growth, now approaching the lower end of fair value. PODD delivered Q1 2026 revenue of $761.7M (+33.9% YoY), with net income and operating cash flow nearly doubling. Management forecasts 21–23% revenue growth in 2026, driven by Omnipod 5 adoption and international expansion, despite competitive threats from weight-loss drugs.

news source

Seeking Alpha • Jun 8, 2026

news preview

Why Is Insulet (PODD) Down 8.7% Since Last Earnings Report?

Insulet (PODD) reported earnings 30 days ago. What's next for the stock?

news source

Zacks Investment Research • Jun 5, 2026

news preview

Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessions

ACTON, Mass.--(BUSINESS WIRE)--Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at ADA.

news source

Business Wire • Jun 4, 2026

news preview

Insulet Corporation (PODD) Presents at 46th Annual William Blair Growth Stock Conference Transcript

Insulet Corporation (PODD) Presents at 46th Annual William Blair Growth Stock Conference Transcript

news source

Seeking Alpha • Jun 3, 2026

news preview

Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor

ACTON, Mass.--(BUSINESS WIRE)--Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor.

news source

Business Wire • Jun 3, 2026

news preview

Insulet (PODD) is a Top-Ranked Growth Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

news source

Zacks Investment Research • Jun 2, 2026

news preview

US court overturns Insulet's $452 mln insulin-pump trade secret verdict against EOFlow

A U.S. ‌appeals court on Thursday overturned a $452 million verdict that ​medical device maker ​Insulet won against Korean rival ⁠EOFlow for allegedly ​stealing trade secrets related ​to its insulin-pump technology.

news source

Reuters • May 28, 2026

news preview

PODD Stock: What a Hold Rating Says at a $163 Target

Insulet earns a short-term Hold as outlook rises; a $163 sales-based target tests whether growth can beat 2026 volatility.

news source

Zacks Investment Research • May 28, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Insulet Corporation

Open an M1 investment account to buy and sell Insulet Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in PODD on M1